Biotech startup Pandorum Technologies has bagged $18 Mn (INR 163 Cr) in a Series B funding round led by Protons Corporate, with participation from Galentic Pharma, Noblevast Advisory and Avinya Fund, Burman Family, alongside existing investor Ashish Kacholia, among others. The fresh capital will be deployed to advance the Bengaluru-based startup’s bid to develop disease-modifying, tunable, exosome-based therapies, including Kuragenx. A portion of the capital will also be allocated to scale its global manufacturing and expand operations across the US, Japan, and the Middle East. “This funding would enable us to translate breakthrough science into programmable, disease-modifying therapies, beginning with single-tissue applications and scaling to multi-tissue repair,” cofounder and CEO Tuhin Bhowmick said. Founded by Bhowmick and Arun Chandru in 2011, Pandorum Technologies is a biotech startup working on regenerating human tissues in the lab. The startup is trying to grow or repair damaged parts of the human body — such as the cornea, liver and lung tissue — using a combination of cells, biomaterials and bio-engineering. Instead of relying on donor organs, the startup develops lab-engineered tissues that can help the body heal or restore lost function. Its lead work includes a bio-engineered corneal therapy aimed at treating corneal… Read MoreInc42 Media
